Expert Speakers Include - Welcome | Veterinary … Oral Use of Antimicrobials in Livestock Farming:...

Optimise Product Development, Drive Innovation and Increase Market Share

24-26 November 2015, Radisson Blu Hotel Berlin, Germany

www.europeanvetsummit.com

Day 1 and Day 2:

Stream 1: R&D of Veterinary Pharmaceutical Medicines

Stream 2: Veterinary Vaccines

Day 3: Registration of Veterinary Medicines

Bookable as a 1 Day

Pass

Media Partners

Expert Speakers Include:

Wolfgang Trunk, Veterinary and International affairs - Animal Nutrition, DG SANCO, EU Commission

Norbert Mencke, VP Global Communications & Public Affairs, Bayer Animal Health

Erwin Blomsma, Vice President, Aratana Therapeutics

Mauro Moraes, Manager of Vectored Vaccines, Ceva Biomune

Mirja Huhtinen, Head of Animal Health, Development R&D, Orion Pharma

Thomas Heberer, Head of Department 3, Veterinary Drugs, Federal Office of Consumer Protection and Food Safety, BVL

Michael Aven, Senior Manager, Pharmaceutical Development, Pharmaceutical Technologies, Boehringer Ingelheim Vetmedica

Jeroen Dewulf, Professor, Ghent University

Day One Tuesday 24 November 2015

Morning Plenary

t: +44 (0)20 7017 7481 e: [email protected] w: www.europeanvetsummit.com 2

08.00 Conference Registration

08.50 Opening Remarks from the Chairperson

MORNING PLENARY

One Health

09.00 INTERACTIVE DISCUSSION PANEL Facilitating the Evolution of One Health by Improving Communication and Collaboration between Human and Animal

Health During this session each speaker will present for 15mins. Talks will be followed by an interactive discussion with the

audience. • How can the animal health industry collaborate with human health to tackle diseases in both areas?

• Do the two industries work closely enough? • Is there a combined R&D strategy between human health and veterinary medicine? • What tool box of reagents can we take from human advances and use in animal health? • One World One Health – how important is this for animal health product development? Expert Speaker Panel: Norbert Mencke, VP Global Communications & Public Affairs, Bayer Animal Health, Germany Erwin Blomsma, Vice President, Aratana Therapeutics, Belgium Ali Mobasheri, Professor of Musculoskeletal Physiology, Head of Department of Veterinary Pre-Clinical Sciences, School of

Veterinary Medicine, University of Surrey, UK

Anitmicrobial Resistance

10.00 KEYNOTE PRESENTATION The Oral Use of Antimicrobials in Livestock Farming: Potential Changes in Legislation and the Alternatives • Antibiotics and antimicrobials with a special focus on coccidiostats • Substitution of antibiotics with different substances COM

• Update on the New Regulations: Medicated Feed Regulation and Authorisation of Veterinary Medicines particularly concerning measures with regards to AMR

Wolfgang Trunk, Veterinary and International Affairs - Animal Nutrition, DG SANCO, EU Commission, Belgium

10.45 Morning Coffee & Exhibition Viewing

11.15 Assessing the Use of Vaccines as Alternatives to Antibiotics • Ensuring early immunization against immunosuppressive diseases of chickens • Examining Gumboro disease • Taking a closer look at Marek’s disease • Detailing the immune foundation • How to decrease of use of antibiotics in production Stephane Lemiere, Global Avian Technical Director, Merial SAS, France

11.45 Examining the Epidemiology of AMR and How to Address this Using Less Antimicrobials • What is driving selection of resistance? • Advice on the miss-use of antibiotics/antimicrobials • Biosecurity as a tool to reduce antimicrobial resistance • The impact of farming practices Jeroen Dewulf, Professor, Ghent University, Belgium

12.15 INTERACTIVE DISCUSSION PANEL AMR - Conclusions, Key Take-Home Messages and Future Outlook Wolfgang Trunk, Veterinary and International affairs - Animal Nutrition, DG SANCO, EU Commission, Belgium COM

Stephane Lemiere, Global Avian Technical Director, Merial SAS, France Jeroen Dewulf, Professor, Ghent University, Belgium 12:45 Lunch & Exhibition Viewing

COM EU CommissionInteractive DiscussionMS Member State

FeedbackOur Vet Summit will address the need for keynote presentations, interactive debate and take-home messages.

Day One Tuesday 24 November 2015

Afternoon Streamed Sessions

t: +44 (0)20 7017 7481 e: [email protected] w: www.europeanvetsummit.comt: +44 (0)20 7017 7481 e: [email protected] w: www.europeanvetsummit.com 3

STREAM 1: R&D OF VETERINARY PHARMACEUTICAL MEDICINES

STREAM 2: VETERINARY VACCINES

Quality by Design and Design of Experiments R&D Strategies

14.00 Development of Veterinary Pharmaceuticals within a Regulatory Framework from Pre-Formulation to Production• Overview of pharmaceutical development of veterinary

pharmaceuticals• Target product profile and quality target (product) profile• Species considerations• Selection of suitable formulation type• Risk assessment, QbD and control strategyMichael Aven, Senior Manager, Pharmaceutical Development, Pharmaceutical Technologies, Boehringer Ingelheim Vetmedica, Germany

Overview of Current Challenges in Global Veterinary Vaccine R&D • Overview • Challenges from the industry• Challenges from clients• Challenges from regulatory agencies• Challenges from the technology Wei Lu, Swine R&D, Ceva Biomune, USA

14.40 WebEx: Learning from the Human Pharmaceutical IndustryDrug Substance Process Development Using the QbD Concept: Assurance of Quality, Speed to Market and Cost Advantage• A brief introduction to QbD• Challenges faced during development• Systematic development of DS process• Identification of DS CQAs and QAs• Design space development using DoE & mechanistic

model• Development of a robust control strategySushil K. Srivastava, Director, Chemical Development (Drug Substance), Pharmaceutical Development, Bristol-Myers Squibb (BMS), USA

14.40 Recombinant Vaccines: Challenges of Incorporating New Technology into Classic Vaccines Models• Long-lasting concept and challenges• Identifying new viruses or diseases to develop vaccines • Vectored platforms • Successful example of the application of vaccine

technology: Avian Influenza experienceMauro Moraes, Manager of Vectored Vaccines, Ceva Biomune, USA

15.20 Spotlight Session Spotlight presentations are hosted by leading service providers within the veterinary field. For more information about hosting a spotlight presentation, please contact Chamatkar Sandhu [email protected] Tel: +44 (0)20 7017 7278

Spotlight Session Spotlight presentations are hosted by leading service providers within the veterinary field. For more information about hosting a spotlight presentation, please contact Chamatkar Sandhu [email protected] Tel: +44 (0)20 7017 7278

16.00 Afternoon Tea & Exhibition Viewing

16.30 Optimising Tabletting Characteristics by Applying DoEClaudius Weiler, Senior Manager, Pharmaceutical Development, Pharmaceutical Technologies, Boehringer Ingelheim Vetmedica, Germany

Design of Novel Vaccines Based on Virus-Like Particles• What makes VLP good vaccine candidate?• The role of size, geometry and molecular patterns in

vaccine design• VLPs as antiviral vaccines• Expression systems for VLPs production• VLPs as platforms for foreign antigen display• Structure-based engineering of VLPs for vaccine

developmentEsther Blanco, Research Scientist, Animal Health Centre (CISA-INIA), Spain

17.10 Emerging Research Advances and New Opportunities in Vaccine Development• New types of vaccines being developed• Which diseases have potential for development? • Mitigation and removal of risk in products• Technology transferral from one species to another Lorenzo José Fraile Sauce, Associate Professor of Epidemiology and Pharmacology, University of Lleida, Spain

17.10 Closing Remarks from the Chairperson 17.50 Closing Remarks from the Chairperson

17.20 End of Day One Followed by Optional Evening Seminar(see page 6 for details)

18.00 End of Day One Followed by Optional Evening Seminar (see page 6 for details)

Day Two Wednesday 25 November 2015

Streamed Sessions

STREAM 1: R&D OF VETERINARY PHARMACEUTICAL MEDICINES

STREAM 2: VETERINARY VACCINES


New APIs Protective Immunity

09.00 Discovery of New APIs for Veterinary Medicines • What are the best strategies for finding new APIs? • What new actives are currently in the pipeline?• Analysis of these APIs• Cost: benefit ratios • Future outlook and impact for the veterinary industry Nesya Goris, VP Discovery Research, Aratana Therapeutics, Belgium

Correlation between Antibody Response and Protection and the Duration of Immunity • What is acceptable in terms of current vaccine efficacy and

duration of immuno-activity? • How much scientific basis is there for revaccination? • Are the guidelines sufficient or is it necessary to revaccinate

more often?A representative from the VMD, UK (subject to confirmation)

Formulation Strategies Development of a Clostridium Perfringens Type A/C Toxoid Vaccine for Sows to Protect Piglets Against the Necrotic Enteritis and Negative Effects of an Infection with Clostridium Perfringens Type A• Choice of the vaccine strain (in vitro testing of the toxin

production)• Development of challenge models to evaluate the efficacy• Determination of antibodies against the toxins in serum and

colostrum (sows)• Evaluation of the relationship between antibodies against the

toxins and the efficacy (challenge model)• Impact of repeated vaccinations of the amount of antibodies

against the toxins Sven Springer, DVM, Animal Health, R&D Department, IDT Biologika GmbH, Germany

09.35 Understanding the Science behind the Formulation • Biopharmaceutical Classification System (BCS) and

the veterinary industry• Formulation and animal specificities• The use of dissolution• In Vitro In Vivo Correlations (IVIVC) as a tool for the

veterinary industry Jean-Michel Cardot, Professor, Université d’Auvergne, France


10.40 Innovation in Adjuvant Design and Production: Supplier’s Perspective• Challenges around making soluble adjuvants • The use of polymers and advantages gained • Benefits to industry of using the adjuvant • Assessing the impact on cost of product If you are interested in presenting on this topic please contact Chamatkar Sandhu [email protected] Tel: +44 (0)20 7017 7278

Formulation Strategies and the Use of Adjuvants

Innovation in Adjuvant Design and Production: Industry Perspective• Which adjuvants to use for which vaccines? • Which adjuvants to use for which species? • How to decide on supplier • Advantages and disadvantages of tried and tested adjuvants

usedJuliano Brandao, Industrial Production Manager, Ourofino Animal Health, Brazil

Clinical Trials Innovation in Adjuvant Design and Production: Supplier’s Perspective• Challenges around making soluble protein adjuvants more

immunogenic• Employment of immunoadjuvants• Variation of immunity across species, delivery methods and

adjuvants• The use of polymers • Impact on cost of vaccines If you are interested in presenting on this topic please contact Chamatkar Sandhu [email protected] Tel: +44 (0)20 7017 7278

11.15 Optimising Clinical Trials in the Veterinary Industry • Outlining the different types of clinical studies• How to plan for a successful trial • The importance of study design and protocol

development• How to validate your primary efficacy endpoint• The importance of planning and communication• Where should you run your study? • Clinical trial troubleshootingMirja Huhtinen, Head of Animal Health, Development R&D, Orion Pharma, Finland

t: +44 (0)20 7017 7481 e: [email protected] w: www.europeanvetsummit.comt: +44 (0)20 7017 7481 e: [email protected] w: www.europeanvetsummit.com 4


Streamed Sessions

R&D of Veterinary Medicines in Brazil Regulatory Affairs in Veterinary Vaccines

11.50 R&D Management in the Pharmaceutical Veterinary Medicine Industry – The Experience of a Brazilian Company• Process of development – steps and activities• Aligning market expectations to product concept• Main challenges and obstacles• Managing risks• Performing clinical trials• Key performance indicatorsGustavo Bezzuoli Mano, Product Development Manager, Vetnil, Brazil

The New Regulation: Regulatory Guidance for Veterinary Vaccines • Outline of the new regulation and impact for the vaccine

industry • Best practices for vet vaccine registration • Difference in regulatory frameworks between traditional

vaccines and advanced technologies vaccines• Registering new platform technologies such as vector

vaccines or stem cellsJavier Martínez de Velasco, Veterinary Medicines Assessor (Immunological Products), AEMPS, Spain

12.25 Lunch & Exhibition Viewing

13.40 INTERACTIVE PANEL DISCUSSIONConclusions and Key Take-Home Messages from this Morning's Presentations

Tackling Emerging Diseases

Emerging Diseases: The Necessity to Develop Products and the Challenges Faced • Current disease ‘hotspots’• Challenges and opportunities• Case for early market access for products in order to react

more quickly• Public or private - who should pay when there is a public

health driver to treat a disease?• ‘Downstream’ processes: Leveraging new technologies cost

effectively• Overcoming economic constraints in developing countries• Modelling of emerging diseases and predicting the spread

and power of certain vaccinesAlex Morrow, Deputy Science Coordinator, Veterinary Science Team, DEFRA, UK

Stability Testing of Veterinary Medicines Aquaculture

14.15 WORKSHOP SESSIONThis session will be in the style of a workshop, with an interactive format consisting of practical exercises and groups discussions. The leader and delegates will openly share their expertise and experiences and learn from each other.

Practical Advice on Developing a Stability Protocol for the Global Market• Understanding the impact of heat and humidity on the

stability of veterinary pharmaceutical products• Establishing a global stability programme that would

cover multiple country requirements with limited tests• Reviewing key differences in country-specific stability

requirements outside the ICH region

Prediction of Shelf-life • Statistical evaluation of stability data• Design of Experiments (DoE)• The benefit of stress tests to achieve faster results • The ASAP approach• “Stability by Design”

Workshop Leader: Manuel Zahn, Managing Director, 3R Pharma Consulting GmbH, Germany

14.15 Fish Vaccines and Vaccination - A short but remarkable journey• History of commercial fish vaccines• Size of the industry• Benefits brought by fish vaccination• Vaccination methods• New technologies now being applied to fish vaccine

development• The future of ‘second -generation’ fish vaccines with

particular reference to registrationPatrick Smith, Managing Director, Tethys Aquaculture, UK

14.50 Quality Control Testing of Fish Vaccines: 3Rs Issues and Development of In Vitro Tests A Representative from the VMD, UK (subject to confirmation)

VLPs

15.25 Self-Assembling Virus-Like Particles in Insect Cells: Production, Purification and Vaccine Potential• Enveloped virus-like particles (eVLPs) are efficiently secreted

from baculovirus-infected insect cells• eVLPs display superior immunogenicity compared to

subunits in animal models• Core-like particles (CLPs) may form a more stable alternative

to eVLPs• eVLPs and CLPs are attractive next-generation vaccinesGorben P. Pijlman, Assistant Professor Virology, Wageningen University, the Netherlands



MS


CLOSING PLENARY

Collaborations between Industry and Academia

16.30 INTERACTIVE PANEL DISCUSSION Partnerships and Collaborations between Industry and Academia • Partnering between academia and industry • Finding an entrepreneurial academic establishment • How to get the most out of a partnership

• When seeking a partnership what factors are considered? • Working in partnership to develop your product • How do universities facilitate tech transfer? • Effects of a more proactive approach on interactions between academia and industry • Examples of collaboration between academia and industry leading to innovative technologies or products Sven Arnouts, Business Developer, PROVAXS and University of Ghent, Belgium Professor Andy Peters, Director, Arpexas, UK

Investment Opportunities

17.05 Investment Opportunities & Venture Capital in Veterinary Medicines • Are there enough EU opportunities for investors? • What are the barriers to investment? • Investment opportunities in veterinary start-ups • How can we nurture and encourage more start-ups? • What do investors look for? • What does a company need to demonstrate before they receive investment? • What areas are investors interested in? • Which products and innovations have been invested in? • Case studies and experiences to date Paul Dick, Managing Partner and President, Vet Venture Capital, Canada

17.40 Closing Remarks from the Chairperson

17.50 End of Day Two

Evening Seminar, Discussion and Dinner: Day 1: Tuesday 24 November 2015

DIAGNOSTICS IN THE VETERINARY INDUSTRYRegistration: 18.00 Start: 18.30 Networking Dinner: 20.30

This informal and interactive evening seminar will be relevant to all those working in the veterinary industry, including but not limited to those involved in the R&D of veterinary pharmaceutical medicines, veterinary vaccines and regulatory affairs professionals working in either/both areas.

Topics to be Covered Include:• Major trends in animal health diagnostics• New technologies on which diagnostics can be built • What are the results? • What factors have influenced current strategies?• How to measure the effectiveness of a solution?• R&D guidance for developing and evaluating the R&D pipeline• Producing a new immunological diagnostics tool box for vet vaccines: Understanding animal immune responses• Veterinary diagnostics and regulatory hurdles • Understanding immune responses in veterinary species• How do we define and measure immune correlates? • How can we drive immune responses to maximize vaccine efficacy? • How do we develop DIVA diagnostics and vaccines? • What are the barriers to progress and how can we overcome these• How does vaccine development for companion animals and livestock species differ and what are the major influencing factors? Seminar Leaders:Professor Gary Entrican, Principal Research Scientist, Moredun Research Institute, UK Professor Andy Peters, Director, Arpexas, UK


Closing Plenary

Day Three Thursday 26 November 2015

08.00 Conference Registration


The New Regulations

09.00 KEYNOTE PRESENTATION Examining the New Regulation: The Medicated Feed Legislation • Reviewing comments from parliament, MS and COM since publication/adoption • Which areas of veterinary medicines will be affected? COM

• What is the timetable for the entry into force of the new regulation? • What should industry do in the transition period? Wolfgang Trunk, Veterinary and International affairs - Animal Nutrition, DG SANCO, EU Commission, Belgium

09.45 Proposal for a New Veterinary Regulation: A Step Forward in the Right Direction? • Which areas will be affected? • What is acceptable, what needs to be amended?

MS • What improvements are possible during the transition period? Cornelia Ibrahim, Head of Unit, Support and Surveillance after Authorisation, Deputy Head of Department, Veterinary Drugs,

Federal Office for Consumer Protection and Food Safety, BVL, Germany

10.20 Examining the New Regulation: Authorisation of Veterinary Medicines – Specific focus on small markets, SMEs and availability of VMPs

• Reviewing comments from parliament, MS and COM since publication/adoption MS • Which areas of veterinary medicines will be affected?

Lucie Pokludová, Assessor of VMP, Institute for State Control of Veterinary Biologicals and Medicaments, Czech Republic


11.25 INTERACTIVE PANEL DISCUSSION The New Regulations: Conclusions, Key Take-Home Messages and Future Outlook

12.00 Spotlight Session Spotlight presentations are hosted by leading service providers within the veterinary field. For more information about hosting

a spotlight presentation, please contact Chamatkar Sandhu [email protected] Tel: +44 (0)20 7017 7278

12.35 Lunch & Exhibition Viewing

Antimicrobial Resistance

14.00 Evaluating European Regulatory Requirements for Antimicrobials • Strategies in place to deal with antimicrobial resistance in MS • Tracking consumption of antibiotics in MS

MS • Advice for dealing with referrals related to antimicrobial resistance • Which ones can be used under reasonable use? What is the definition of this? Professor Thomas Heberer, Head of Department 3, Veterinary Drugs, Federal Office of Consumer Protection and Food

Safety, BVL, Germany

14.35 Factors Influencing Antibiotic Prescribing Habits and Use of Sensitivity Testing Amongst Veterinarians in Europe • Which factors influence antibiotic prescribing? • Which information sources use vets to decide antibiotic prescribing? • What is the effect of guidelines and recommendations? MS

• Frequency and reasons to do sensitivity testing across Europe • Challenges in respect to sensitivity testing Nancy De Briyne, Deputy Executive Director FVE, Federation of Veterinarians of Europe, Belgium

REGISTRATION OF VETERINARY MEDICINESExamining the Regulatory Requirements for Veterinary Pharmaceutical

Medicines, Vaccines and Biologicals


Bookable as a 1 Day

Pass



Harmonization of SPCs for Generics

15.40 The Process of Harmonizing SPCs via Generic Procedures: How Does it Work? How Far will it go? • Outlining the process of creation of SPCs for generics • Explanation of how, through these generic procedures, the Member States create “harmonized SPCs”

MS • Practical case studies of where harmonized claims, warnings or withdrawal periods have been created by the Member States in collaboration with the applicant

• Discussion of how the harmonized SPCs can be applied to the reference products Sylvie Louet, Rapporteur, Pharmaceuticals Assessment Unit, ANSES, France

Pharmacovigilance and VMPs Postmarketing Surveillance

16.15 Pharmacovigilance Inspections and EU Harmonisation and VMPs Postmarketing Surveillance

MS Remedios Ezquerra Plasencia, Head of Service, Pharmacovigilance, Quality Defects, Foreign Trade and Illegal Veterinary

Medicinal Products Area, Veterinary Medicines Department, Spanish Medicines Agency (AEMPS), Spain

E-Submissions

16.50 Latest Updates on Veterinary E-Submissions • E-submission roadmap, single submission portal • Harmonised processing and validation in Europe • Overview on latest version of the veterinary e-submission guideline 2.3 and validation criteria + VNeeS checkerMS

• VICH guideline 53 Electronic file format • Electronic application form (eAF) Pieter Vankeerberghen, Head, ICT Developments and Projects, AFMPS, Belgium

17.25 Closing Remarks from the Chairperson

17.35 End of Day 3 Followed by Evening Seminar

Evening Seminar, Discussion and Dinner: Thursday 26 November 2015

ENVIRONMENTAL RISK ASSESSMENT18:15 Registration • 18:30 Start • 20:30 Networking Dinner

During this informal and interactive session attendees will hear from Member States and the Fraunhofer ITEM on the subject of ERA in order to gain in-depth regulatory and technical knowledge. Presentations will be followed by group discussions led by speakers whereby delegates will exchange real-life experiences. Leave the conference with key take home messages that you can implement in your day-to-day role.

Environmental Risk Assessment of VMPs• Basis of the Environmental Risk Assessment • ERA for terrestrial animals and ERA for aquatic animals• Dealing with the extractability from soil • PBT substances• Endocrine Disruptors Ricardo Carapeto García, Environmental Risk Assessor, Spanish Agency of Medicines and Medical Devices, Spain

Challenges and Future Perspectives of Environmental Risk Assessment• Environmental aspects in the proposal for a new veterinary regulation – what is acceptable, what needs to be amended?• Challenges for research and legislation: PBT substances, antimicrobial resistance, tailored ERA• Eco-Pharmacovigilance in the post market surveillanceInes Rönnefahrt, Senior Risk Assessor, Federal Environment Agency (UBA), Germany

Environmental Risk Assessments - Requirements, Strategies and Latest News• Legal background for an ERA for VMPs • Requirements and studies• Costs and cost sharing • Latest changes of regulation (EMA, CVMP)Susanne Schwonbeck, Senior Risk Assessor, Fraunhofer Institute for Toxicology and Experimental Medicine, Fraunhofer ITEM, Germany

INTERACTIVE DISCUSSION PANELEnvironmental Risk Assessment: Conclusions, Key Take-Home Messages and Future Outlook

MS

MS

Day Three Thursday 26 November 2015

Our Vet Summit is a combination of our existing veterinary conferences previously held in separate locations

4th Annual R&D of Veterinary Pharmaceutical Medicines

10th Annual Veterinary Vaccines

10th Annual Registration of Veterinary Medicines

www.europeanvetsummit.com

3 Audiences – 1 Location Vet Summit Vital Statistics:

Sponsorship and Exhibition Opportunities

150+ Attendees

100+ Companies Represented

10+ Hours of NetworkingFor more information on the opportunities

available please contact

Chamatkar Sandhu, Business Development Manager, +44 (0) 20 7017 7278, [email protected]


Past Veterinary Conference Sponsors and Exhibitors Include:

Be part of Vet Summit 2015!Informa's Vet Summit will provide you with flexible and tailored solutions which optimise your investment whilst meeting your specific business development requirements. If you’re interested in any of the benefits outlined please

Contact: Chamatkar Sandhu [email protected]: +44 (0)20 7017 7278

Geographical Breakdown of

2014 Attendees*Based on previous vet

conferences

• Present a service or technology on the conference programme and position yourself alongside a selection of the sector’s most important decision-makers - LIMITED SPACES AVAILABLE

• Build brand awareness amongst industry’s best through an exhibition stand and extensive marketing opportunities that guarantee you achieve high visibility

• Build relationships with existing as well as potential new customers at the networking drinks reception

• Meet and partner with new companies in our high speed networking session

Enquire now to ensure you don’t miss out on this exciting NEW event!

Partnering Opportunities at Vet Summit 2015

2014 Attendee Profile*Based on previous vet conferences

55% Director/Head/ Manager

28% R&D/Scientist

16% CEO/VP/President

8% Academic

8% Commercial

t: +44 (0)20 7017 7481 e: [email protected] w: www.europeanvetsummit.com

Optimise Product Development, Drive Innovation and Increase Market Share

24-26 November 2015, Radisson Blu Hotel Berlin, Germany


Western Europe 63%

RoW 22%

Northern Europe 7%

Southern Europe 5%

Eastern Europe 3%

,,

This is a fabulous networking event bringing together the people who are driving the R&D platforms of the animal health industry with those who have a product or technology that may be applicable

Flad Architects, R&D Veterinary Medicines 2013 Delegate

,,

24-26 November 2015

Radisson Blu Hotel Berlin, Germany

Group Bookings:To take advantage of group bookings,

please contact Simon Lau on+ 44 (0) 20 70 17 7165 or email

[email protected]

#vetsummit2015@InformaVet

Terms and Conditions

3 EASY WAYS TO REGISTER

DELEGATE DETAILS – Please photocopy form for multiple bookings!

FEE: This includes all technical sessions, refreshments, lunch and access to speaker presentations that we have permission to make available.CANCELLATIONS: Cancellations received in writing before and on 10 November 2015 will be subject to a service charge of £99. The full conference fees remain payable after 10 November 2015. Substitutions are welcome at any time. It may be necessary for reasons beyond the control of the organiser to alter the content and timing of the programme or the identity of the speakers. In the unfortunate event that an event is cancelled Informa are not liable for any costs incurred by delegates in connection with their attendance. This contract is subject to English Law.ARE YOU REGISTERED?: You will always receive an acknowledgement of your booking. If you do not receive anything please call +44 (0)20 7017 7481 to make sure we have registered your booking.ANY SPECIAL REQUIREMENTS?: Please inform us if you have any special requirements by calling +44 (0)20 7017 7481

DATA PROTECTION: The personal information shown on this form, and/or provided by you, will be held on a database and may be shared with other companies in the Informa Group in the UK and internationally. If you do not wish your details to be available to companies in the Informa Group please contact the Database Manager at Maple House, 149 Tottenham Court Road, London, W1T 7AD, Tel : +44 (0)20 7017 7077, Fax: +44 (0)20 7017 7828 or email: [email protected]. Occasionally your details may be obtained from, or made available to, external companies who wish to communicate with you offers related to your business activities. If you do not wish to receive these offers, please tick the box nINCORRECT MAILING: If you are receiving multiple mailings or you would like us to change any details or remove your name from our database, please contact the Database Manager at the above address, Tel +44 (0)20 7017 7077, Fax +44 (0)20 7017 7828 or email: [email protected] - quoting the reference number printed on the mailing label

VENUE DETAILS: Radisson Blu Hotel, Berlin, Karl-Liebknecht-Strasse 3, D-10178, Berlin, Germany Phone +49 30 238 280www.radissonblu.com/hotel-berlin

REDUCED RATE ACCOMMODATION: Delegates are responsible for the arrangement and payment of their own travel and accommodation. Informa has negotiated a special room rate at the event venue and a number of hotels nearby, to take advantage please visit the “Accommodation” page on the conference website: www.europeanvetsummit.com. Please book early to avoid disappointment

To make payment by credit card: to ensure we provide the highest level of security for your credit card details we are unable to accept such payments via email or fax which ensures that these details are never stored on our network. To make payment by credit card on-line, please enter your credit card details in our secure payments website that you will use when making your booking via the event website (the event web address is near the top of the booking form). Alternatively call our customer service team on +44 (0) 20 7017 7481. Due to unforeseen circumstances, the programme may change and Informa reserves the right to alter the venue and/or speakers. ©Copyright Informa BV, 2015

NOTE: The VAT rate is subject to change and may differ from the advertised rate.The amount you are charged will be determined when your invoice is raised. Informa Life Sciences will verify whether you are a vendor/supplier when your registration is processed.

CONFERENCE DOCUMENTATION: CANNOT ATTEND?For those busy executives who cannot take full advantage of this event, the CD gives you a useful record of the presentations made at the event. The set of speakers papers and/or slides in CD format from the conference is available after the event for £499 + 20% VAT. UK VAT: The VAT rate is subject to change and may differ from the advertised rate. The amount you are charged will be determined when your invoice is raised. Contact Customer Services on tel: +44 (0) 20 7017 7481, fax +44 (0) 20 7017 7823 or e-mail: [email protected]

To assist us with future correspondence, please supply the following details:

No. of employees on your site:

(Mr/Mrs/Ms/Miss/Dr) Family Name

Head of Department: Address

Booking Contact: Tel Fax

Forename

E-mail

E-mail

E-mail Customer VAT Number

Job Title

City

Nature of Company Business

1) 0-49 n 2) 50-249 n 3) 250-499 n 4) 500-999 n 5) 1000+ n

Any special requirements?

Tel Fax

Tel Fax Postcode Country

Tel Fax

Name of Company/Department

Please Select Your Pass: Book Before

4 September 2015 SAVE Book Between 4 September & 23 October 2015 SAVE Book After

23 October 2015 SAVE

1 Day Conference (only available for Day 3) £699 + VAT £200 £799 + VAT £100 £899 + VAT

2 Day Conference £1399 + VAT £200 £1499 + VAT £100 £1599 + VAT

3 Day Conference £2199 + VAT £200 £2299 + VAT £100 £2399 + VAT

Please Select Your Stream(s) Stream 1: R & D of Veterinary Pharmaceutical Medicines (A) OR Stream 2: Veterinary Vaccines (B)

Day 3: Registration of Veterinary Medicines (C) (1 day pass seperately bookable or available as a package with either one of the tracks above)

Upgrade Your Pass:Individual Evening Seminar* £400 + VAT (Book a 3 Day Conference Pass and 2x evening seminars and get one for FREE)

Please Select Your Seminar(s) Day 1: Evening Seminar: Diagnostics in the Veterinary Industry (E) Day 3: Evening Seminar: Environmental Risk Assessment (S)

CQ8206

[email protected]+44 (0)20 7017 7481 www.europeanvetsummit.com

Expert Speakers Include - Welcome | Veterinary … Oral Use of Antimicrobials in Livestock Farming:...

Documents

Transcript of Expert Speakers Include - Welcome | Veterinary … Oral Use of Antimicrobials in Livestock Farming:...